GlassScriptPhysician profile
Jennifer E Davis
NPI 1447572136
$4,099.10
in general payments reported to CMS, 2019-2025
32 companies · $835 in 2025
The $835 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $368 · 2022: $653 · 2023: $1,336 · 2024: $907 · 2025: $835.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,004 · Education: $73.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,003.98 |
| Education | $73.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $832.93 | 2022-2025 | |
| Lilly USA, LLC | $350.48 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $347.45 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $336.96 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $276.55 | 2021-2025 | Repatha, Repatha, Evenity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $262.59 | 2023-2025 | Caplyta |
| Glaxosmithkline, LLC. | $239.56 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Vanda Pharmaceuticals INC. | $214.94 | 2022-2024 | Fanapt, Hetlioz |
| Merck Sharp & Dohme LLC | $166.87 | 2021-2023 | Januvia, Belsomra, Steglatro |
| Exact Sciences Corporation | $139.19 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.89 | 2021-2025 | Jardiance |
| Astellas Pharma US INC | $91.18 | 2023 | Myrbetriq, Veozah |
| Lundbeck LLC | $79.83 | 2022-2025 | Rexulti |
| Xeris Pharmaceuticals, INC. | $67.45 | 2023-2025 | Gvoke Hypopen |
| Corium, LLC | $63.70 | 2023-2024 | Azstarys |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $63.19 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.73 | 2022-2023 | Xifaxan, Trulance |
| Nestle Healthcare Nutrition INC. | $58.07 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $44.98 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $37.85 | 2021-2023 | Uzedy |
| Cequr Corporation | $36.77 | 2024 | Cequr Simplicity |
| Pfizer INC. | $32.21 | 2021-2024 | |
| Sunovion Pharmaceuticals INC. | $23.42 | 2022 | |
| Boston Scientific Corporation | $22.38 | 2025 | Watchman Access System |
| Regeneron Healthcare Solutions, INC. | $21.25 | 2023 | Dupixent |
| Mylan Specialty L.P. | $16.91 | 2021 | |
| Daiichi Sankyo INC. | $16.44 | 2022 | |
| Medtronic, INC. | $16.36 | 2023 | Minimed 780g |
| Abbott Laboratories | $15.82 | 2025 | Freestyle Libre 3 |
| Idorsia Pharmaceuticals US INC | $14.71 | 2024 | Quviviq |
| Phadia US INC. | $14.43 | 2025 | Immunocap |
| Dexcom, INC. | $13.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.